# Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

> **NCT05928806** · PHASE2 · SUSPENDED · sponsor: **Michael B. Atkins, MD** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** Botensilimab
- **DRUG:** Balstilimab
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05928806
- **Lead sponsor:** Michael B. Atkins, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-09-25
- **Primary completion:** 2026-11-10
- **Final completion:** 2027-11-10
- **Target enrollment:** 120 (ESTIMATED)
- **Why stopped:** Interim Analysis
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05928806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05928806, "Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05928806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*